These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 25060664)

  • 1. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer.
    Komai Y; Kawakami S; Numao N; Fujii Y; Saito K; Kubo Y; Koga F; Kumagai J; Yamamoto S; Yonese J; Ishikawa Y; Fukui I; Kihara K
    BJU Int; 2012 Dec; 110(11 Pt B):E564-9. PubMed ID: 22757686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens.
    Park EA; Lee HJ; Kim KG; Kim SH; Lee SE; Choe GY
    Int J Urol; 2007 Aug; 14(8):704-8. PubMed ID: 17681059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings.
    Karram S; Trock BJ; Netto GJ; Epstein JI
    Am J Surg Pathol; 2011 Sep; 35(9):1351-5. PubMed ID: 21836493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.
    Villa L; Capitanio U; Briganti A; Abdollah F; Suardi N; Salonia A; Gallina A; Freschi M; Russo A; Castiglione F; Bianchi M; Rigatti P; Montorsi F; Scattoni V
    J Urol; 2013 Mar; 189(3):854-9. PubMed ID: 23022004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How accurate is our clinical prediction of "minimal prostate cancer"?
    Leibovici D; Shikanov S; Gofrit ON; Zagaja GP; Shilo Y; Shalhav AL
    Isr Med Assoc J; 2013 Jul; 15(7):359-63. PubMed ID: 23943981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
    Ellis CL; Partin AW; Han M; Epstein JI
    J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.
    Villa L; Salonia A; Capitanio U; Scattoni V; Abdollah F; Suardi N; Dell'Oglio P; Freschi M; Montorsi F; Briganti A
    Urology; 2014 Sep; 84(3):634-41. PubMed ID: 25059594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.